HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- High-dose IV vitamin C doubles pancreatic cancer survival Josh Friedman
-
- Novel amifostine delivery could be ‘tremendous advance’ for pancreatic cancer therapy Josh Friedman
- Blood test may improve detection of early pancreatic cancer Josh Friedman
- Cancer clinical trials commonly use ‘two most inaccurate’ tests to measure kidney function Josh Friedman
- Depression among people with head and neck cancers likely underreported, undertreated Josh Friedman
- Dexamethasone benefits in multiple myeloma ‘fade into oblivion’ after a couple months Josh Friedman
- Findings reveal ‘crucial’ need to manage immune checkpoint inhibitor-induced myocarditis Josh Friedman
- First-line regimen improves PFS in chronic lymphocytic leukemia Josh Friedman
- Imlunestrant alone, with abemaciclib delays progression of advanced breast cancer Mark Leiser
-
- In-clinic mental health, cognitive screening can benefit patients with sickle cell disease Jennifer Byrne
- Q&A: Lower blood thinner dose can reduce bleeding risk Jennifer Byrne
- Many patients with cancer do not have access to clinical trials based on where they live Josh Friedman
- ‘More work to do’ to determine cost-effectiveness of universal Duffy testing Josh Friedman
- Most patients with sickle cell disease not prescribed disease-modifying therapy Jennifer Byrne
- Oral bacteria may be biomarker to predict risk for head, neck cancers Josh Friedman
- Risk-reducing surgeries extend survival among young BRCA carriers with breast cancer history Mark Leiser
- Statins may enhance effectiveness of immune checkpoint inhibitors Matthew Shinkle
-
- Survey highlights disparities in cancer pain management, need for cannabis guidelines Jennifer Byrne
- Tandem non-cryopreserved CAR-T exhibits ‘favorable’ activity in advanced DLBCL Josh Friedman
- Targeted therapies for breast cancer increase thrombosis risk Matthew Shinkle
- Trial of vaccine for triple-negative breast cancer yields ‘encouraging’ results Josh Friedman